Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | UBE2N | P61088 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
| ▸ | SLC22A4 | Q9H015 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21345745 | 0.84 | KMT2A (0.54) | KMT2ATDP1KDM3BKDM4EMEN1 | |
| SCHEMBL1691795 | 0.81 | KMT2A (0.55) | KMT2ATDP1KDM3BKDM4EMEN1 | |
| SCHEMBL7070324 | 0.80 | GAA (0.50) | GAAMAPTALDH1A1 | |
| SCHEMBL10983716 | 0.78 | KMT2A (0.53) | KMT2ATDP1KDM3BKDM4EMEN1 | |
| SCHEMBL11343851 | 0.77 | KMT2A (0.51) | KMT2ATDP1KDM3BKDM4EGAA | |
| SCHEMBL1227831 | 0.76 | KMT2A (0.62) | KMT2ATDP1KDM3BKDM4EMEN1 | |
| SCHEMBL10735494 | 0.75 | KMT2A (0.50) | KMT2ATDP1KDM3BKDM4EALDH1A1 | |
| SCHEMBL9108064 | 0.75 | KMT2A (0.57) | KMT2ATDP1KDM3BKDM4EMEN1 | |
| SCHEMBL18640323 | 0.74 | KMT2A (0.60) | KMT2ATDP1KDM3BKDM4EMEN1 | |
| SCHEMBL9109566 | 0.74 | KMT2A (0.46) | KMT2ATDP1KDM3BMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266841-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-20150045375-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-02-12 | — | — | US | disclosed |
| US-8871775-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-20120172378-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20100144765-A1 | 5,6-TRIMETHYLENEPYRIMIDIN-4-ONE COMPOUNDS | HICKEY DEIDRE MARY BERNADETTE | 2010-06-10 | — | — | US | disclosed |
| US-7652019-B2 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an antioxidant probucol; inhibitor of platlet activating factor acetylhydrolase | SMITHKLINE BEECHAM PLC (GB) | 2010-01-26 | — | — | US | disclosed |
| US-7638520-B2 | platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis | SMITHKLINE BEECHAM, PLC (GB) | 2009-12-29 | — | — | US | disclosed |
| EP-1686119-B1 | Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2009-07-29 | — | — | EP | disclosed |
| US-20090170877-A1 | 5,6-Trimethylenepyrimidin-4-one compounds | SMITHKLINE BEECHAM P.L.C. | 2009-07-02 | — | — | US | disclosed |
| US-20090118313-A1 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an antioxidant probucol; inhibitor of platlet activating factor acetylhydrolase | SMITHKLINE BEECHAM P.L.C. | 2009-05-07 | — | — | US | disclosed |
| US-7153861-B2 | For therapy of atheroscelerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-12-26 | — | — | US | disclosed |
| EP-1686119-A1 | PYRIMIDINE-4-ONE DERIVATIVES AS LDL-PLA2 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2006-08-02 | — | — | EP | disclosed |
| EP-1263740-B1 | PYRIMIDINE-4-ONE DERIVATIVE AS LDL-PLA2 INHIBITOR | SMITHKLINE BEECHAM PLC (GB) | 2006-07-19 | — | — | EP | disclosed |
| CN-1179952-C | Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors | ʷ | 2004-12-15 | — | — | CN | disclosed |
| US-20040097525-A1 | For therapy of atheroscelerosis | SMITHKLINE BEECHAM PLC | 2004-05-20 | — | — | US | disclosed |
| US-6649619-B1 | 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl) benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimeth ylenepyrimidin-4-one or salt; lipoprotein-associated phospholipase A inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-11-18 | — | — | US | disclosed |
| CN-1418199-A | Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2003-05-14 | — | — | CN | disclosed |
| EP-1263740-A1 | PYRIMIDINE-4-ONE DERIVATIVES AS LDL-PLA2 INHIBITORS | SmithKline Beecham plc (GB) | 2002-12-11 | — | — | EP | disclosed |
| US-20020103213-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-08-01 | — | — | US | disclosed |
| WO-2001060805-A1 | PYRIMIDINE-4-ONE DERIVATIVES AS LDL-PLA2 INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170877-A1 | 5,6-Trimethylenepyrimidin-4-one compounds | PLA2G4A, PLA2G4B, PLA2G1B | KMT2A 2853/4885TDP1 1689/4885KDM3B 2495/4885 |
| US-20090118313-A1 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an antioxidant probucol; inhibitor of platlet activating factor acetylhydrolase | PLAT, PLA2G7, LYPLAL1 | KMT2A 3864/4885TDP1 1501/4885KDM3B 3866/4885 |
| US-20150045375-A1 | NOVEL COMPOUNDS | PLA2G7, ALOX15B, PLA2G1B | KMT2A 3328/4885TDP1 1737/4885KDM3B 3005/4885 |
| US-20120172378-A1 | NOVEL COMPOUNDS | PLA2G7, ALOX15B, PLA2G1B | KMT2A 3328/4885TDP1 1737/4885KDM3B 3005/4885 |
| US-20040097525-A1 | For therapy of atheroscelerosis | LYPLA2, LOXL2, LYPLA1 | KMT2A 2375/4885TDP1 543/4885KDM3B 2877/4885 |
| US-20100144765-A1 | 5,6-TRIMETHYLENEPYRIMIDIN-4-ONE COMPOUNDS | PLA2G4A, PLA2G4B, PLA2G1B | KMT2A 2853/4885TDP1 1689/4885KDM3B 2495/4885 |
| US-20020103213-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | LYPLAL1, ENPP2, LYPLA2 | KMT2A 2598/4885TDP1 807/4885KDM3B 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.